FCGR2A and metastatic colorectal cancer: In conclusion, this analysis confirms that FCGR2A H/H polymorphism in patients with wild‐type KRAS metastatic colorectal cancer treated with cetuximab is associated with significantly longer OS without affecting toxicity profiles.